Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
73
HRMY Quote, Financials, Valuation and Earnings
Last price:
$38.88
Seasonality move
:
-9.03%
Day range:
$37.47 - $38.91
52-week range:
$25.52 - $40.93
Dividend yield:
0%
P/E ratio:
12.24x
P/S ratio:
2.75x
P/B ratio:
2.68x
Volume:
692.4K
Avg. volume:
793.1K
1-year change:
13.36%
Market cap:
$2.2B
Revenue:
$714.7M
EPS (TTM):
$3.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HRMY
Harmony Biosciences Holdings, Inc.
|
$222.7M | $0.86 | 18.24% | 27.84% | $46.18 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$212.9M | $1.77 | 21.97% | 68.6% | $109.25 |
|
CAPR
Capricor Therapeutics, Inc.
|
$480K | -$0.54 | -100% | -240.06% | $50.80 |
|
HALO
Halozyme Therapeutics, Inc.
|
$339.1M | $1.63 | 32.42% | 80.55% | $76.00 |
|
MRNA
Moderna, Inc.
|
$869.9M | -$2.16 | -34.46% | -5.24% | $36.75 |
|
NRIX
Nurix Therapeutics, Inc.
|
$13.4M | -$0.92 | -9.4% | -23.71% | $28.41 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HRMY
Harmony Biosciences Holdings, Inc.
|
$38.86 | $46.18 | $2.2B | 12.24x | $0.00 | 0% | 2.75x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$80.72 | $109.25 | $1.8B | 49.50x | $0.00 | 0% | 1.97x |
|
CAPR
Capricor Therapeutics, Inc.
|
$29.50 | $50.80 | $1.3B | -- | $0.00 | 0% | 120.31x |
|
HALO
Halozyme Therapeutics, Inc.
|
$68.16 | $76.00 | $8B | 14.33x | $0.00 | 0% | 6.88x |
|
MRNA
Moderna, Inc.
|
$34.90 | $36.75 | $13.6B | -- | $0.00 | 0% | 6.06x |
|
NRIX
Nurix Therapeutics, Inc.
|
$19.34 | $28.41 | $1.5B | -- | $0.00 | 0% | 19.07x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HRMY
Harmony Biosciences Holdings, Inc.
|
21.38% | 0.639 | 14.3% | 3.46x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.550 | 30.7% | 2.40x |
|
CAPR
Capricor Therapeutics, Inc.
|
17.61% | 1.632 | 5.44% | 3.50x |
|
HALO
Halozyme Therapeutics, Inc.
|
74.99% | -0.702 | 17.53% | 1.26x |
|
MRNA
Moderna, Inc.
|
7.29% | 0.934 | 7.28% | 3.30x |
|
NRIX
Nurix Therapeutics, Inc.
|
13.18% | 2.105 | 7.87% | 5.21x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HRMY
Harmony Biosciences Holdings, Inc.
|
$173.8M | $65.5M | 19.81% | 25.9% | 27.35% | $108.7M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
CAPR
Capricor Therapeutics, Inc.
|
-$494.7K | -$26.3M | -72.3% | -77.32% | -69.16% | -$23.7M |
|
HALO
Halozyme Therapeutics, Inc.
|
$281.3M | $217.9M | 30.69% | 139.43% | 61.51% | $175.6M |
|
MRNA
Moderna, Inc.
|
$757M | -$260M | -27.85% | -30.18% | -25.59% | -$880M |
|
NRIX
Nurix Therapeutics, Inc.
|
$2.9M | -$91.4M | -51.1% | -55.52% | -1157.65% | -$60.1M |
Harmony Biosciences Holdings, Inc. vs. Competitors
-
Which has Higher Returns HRMY or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of 21.24% compared to Harmony Biosciences Holdings, Inc.'s net margin of 10.59%. Harmony Biosciences Holdings, Inc.'s return on equity of 25.9% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings, Inc.72.6% $0.87 $1.1B ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About HRMY or ANIP?
Harmony Biosciences Holdings, Inc. has a consensus price target of $46.18, signalling upside risk potential of 18.84%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $109.25 which suggests that it could grow by 35.34%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Harmony Biosciences Holdings, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Harmony Biosciences Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings, Inc.7 1 0 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is HRMY or ANIP More Risky?
Harmony Biosciences Holdings, Inc. has a beta of 0.801, which suggesting that the stock is 19.902% less volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.639%.
-
Which is a Better Dividend Stock HRMY or ANIP?
Harmony Biosciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HRMY or ANIP?
Harmony Biosciences Holdings, Inc. quarterly revenues are $239.5M, which are larger than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Harmony Biosciences Holdings, Inc.'s net income of $50.9M is higher than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio is 12.24x while ANI Pharmaceuticals, Inc.'s PE ratio is 49.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings, Inc. is 2.75x versus 1.97x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings, Inc.2.75x 12.24x $239.5M $50.9M ANIPANI Pharmaceuticals, Inc.1.97x 49.50x $227.8M $24.1M
-
Which has Higher Returns HRMY or CAPR?
Capricor Therapeutics, Inc. has a net margin of 21.24% compared to Harmony Biosciences Holdings, Inc.'s net margin of -63.94%. Harmony Biosciences Holdings, Inc.'s return on equity of 25.9% beat Capricor Therapeutics, Inc.'s return on equity of -77.32%.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings, Inc.72.6% $0.87 $1.1B CAPRCapricor Therapeutics, Inc.-- -$0.54 $101.8M -
What do Analysts Say About HRMY or CAPR?
Harmony Biosciences Holdings, Inc. has a consensus price target of $46.18, signalling upside risk potential of 18.84%. On the other hand Capricor Therapeutics, Inc. has an analysts' consensus of $50.80 which suggests that it could grow by 72.2%. Given that Capricor Therapeutics, Inc. has higher upside potential than Harmony Biosciences Holdings, Inc., analysts believe Capricor Therapeutics, Inc. is more attractive than Harmony Biosciences Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings, Inc.7 1 0 CAPRCapricor Therapeutics, Inc.8 0 0 -
Is HRMY or CAPR More Risky?
Harmony Biosciences Holdings, Inc. has a beta of 0.801, which suggesting that the stock is 19.902% less volatile than S&P 500. In comparison Capricor Therapeutics, Inc. has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.632%.
-
Which is a Better Dividend Stock HRMY or CAPR?
Harmony Biosciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Capricor Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings, Inc. pays -- of its earnings as a dividend. Capricor Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or CAPR?
Harmony Biosciences Holdings, Inc. quarterly revenues are $239.5M, which are larger than Capricor Therapeutics, Inc. quarterly revenues of --. Harmony Biosciences Holdings, Inc.'s net income of $50.9M is higher than Capricor Therapeutics, Inc.'s net income of -$24.6M. Notably, Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio is 12.24x while Capricor Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings, Inc. is 2.75x versus 120.31x for Capricor Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings, Inc.2.75x 12.24x $239.5M $50.9M CAPRCapricor Therapeutics, Inc.120.31x -- -- -$24.6M
-
Which has Higher Returns HRMY or HALO?
Halozyme Therapeutics, Inc. has a net margin of 21.24% compared to Harmony Biosciences Holdings, Inc.'s net margin of 49.46%. Harmony Biosciences Holdings, Inc.'s return on equity of 25.9% beat Halozyme Therapeutics, Inc.'s return on equity of 139.43%.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings, Inc.72.6% $0.87 $1.1B HALOHalozyme Therapeutics, Inc.79.39% $1.43 $2B -
What do Analysts Say About HRMY or HALO?
Harmony Biosciences Holdings, Inc. has a consensus price target of $46.18, signalling upside risk potential of 18.84%. On the other hand Halozyme Therapeutics, Inc. has an analysts' consensus of $76.00 which suggests that it could grow by 11.5%. Given that Harmony Biosciences Holdings, Inc. has higher upside potential than Halozyme Therapeutics, Inc., analysts believe Harmony Biosciences Holdings, Inc. is more attractive than Halozyme Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings, Inc.7 1 0 HALOHalozyme Therapeutics, Inc.4 2 1 -
Is HRMY or HALO More Risky?
Harmony Biosciences Holdings, Inc. has a beta of 0.801, which suggesting that the stock is 19.902% less volatile than S&P 500. In comparison Halozyme Therapeutics, Inc. has a beta of 0.948, suggesting its less volatile than the S&P 500 by 5.224%.
-
Which is a Better Dividend Stock HRMY or HALO?
Harmony Biosciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings, Inc. pays -- of its earnings as a dividend. Halozyme Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or HALO?
Harmony Biosciences Holdings, Inc. quarterly revenues are $239.5M, which are smaller than Halozyme Therapeutics, Inc. quarterly revenues of $354.3M. Harmony Biosciences Holdings, Inc.'s net income of $50.9M is lower than Halozyme Therapeutics, Inc.'s net income of $175.2M. Notably, Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio is 12.24x while Halozyme Therapeutics, Inc.'s PE ratio is 14.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings, Inc. is 2.75x versus 6.88x for Halozyme Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings, Inc.2.75x 12.24x $239.5M $50.9M HALOHalozyme Therapeutics, Inc.6.88x 14.33x $354.3M $175.2M
-
Which has Higher Returns HRMY or MRNA?
Moderna, Inc. has a net margin of 21.24% compared to Harmony Biosciences Holdings, Inc.'s net margin of -19.69%. Harmony Biosciences Holdings, Inc.'s return on equity of 25.9% beat Moderna, Inc.'s return on equity of -30.18%.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings, Inc.72.6% $0.87 $1.1B MRNAModerna, Inc.74.51% -$0.51 $10.1B -
What do Analysts Say About HRMY or MRNA?
Harmony Biosciences Holdings, Inc. has a consensus price target of $46.18, signalling upside risk potential of 18.84%. On the other hand Moderna, Inc. has an analysts' consensus of $36.75 which suggests that it could grow by 5.3%. Given that Harmony Biosciences Holdings, Inc. has higher upside potential than Moderna, Inc., analysts believe Harmony Biosciences Holdings, Inc. is more attractive than Moderna, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings, Inc.7 1 0 MRNAModerna, Inc.3 16 1 -
Is HRMY or MRNA More Risky?
Harmony Biosciences Holdings, Inc. has a beta of 0.801, which suggesting that the stock is 19.902% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.
-
Which is a Better Dividend Stock HRMY or MRNA?
Harmony Biosciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or MRNA?
Harmony Biosciences Holdings, Inc. quarterly revenues are $239.5M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Harmony Biosciences Holdings, Inc.'s net income of $50.9M is higher than Moderna, Inc.'s net income of -$200M. Notably, Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio is 12.24x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings, Inc. is 2.75x versus 6.06x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings, Inc.2.75x 12.24x $239.5M $50.9M MRNAModerna, Inc.6.06x -- $1B -$200M
-
Which has Higher Returns HRMY or NRIX?
Nurix Therapeutics, Inc. has a net margin of 21.24% compared to Harmony Biosciences Holdings, Inc.'s net margin of -1094.77%. Harmony Biosciences Holdings, Inc.'s return on equity of 25.9% beat Nurix Therapeutics, Inc.'s return on equity of -55.52%.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings, Inc.72.6% $0.87 $1.1B NRIXNurix Therapeutics, Inc.36.66% -$1.03 $428.7M -
What do Analysts Say About HRMY or NRIX?
Harmony Biosciences Holdings, Inc. has a consensus price target of $46.18, signalling upside risk potential of 18.84%. On the other hand Nurix Therapeutics, Inc. has an analysts' consensus of $28.41 which suggests that it could grow by 46.91%. Given that Nurix Therapeutics, Inc. has higher upside potential than Harmony Biosciences Holdings, Inc., analysts believe Nurix Therapeutics, Inc. is more attractive than Harmony Biosciences Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings, Inc.7 1 0 NRIXNurix Therapeutics, Inc.12 1 0 -
Is HRMY or NRIX More Risky?
Harmony Biosciences Holdings, Inc. has a beta of 0.801, which suggesting that the stock is 19.902% less volatile than S&P 500. In comparison Nurix Therapeutics, Inc. has a beta of 1.874, suggesting its more volatile than the S&P 500 by 87.383%.
-
Which is a Better Dividend Stock HRMY or NRIX?
Harmony Biosciences Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nurix Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings, Inc. pays -- of its earnings as a dividend. Nurix Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or NRIX?
Harmony Biosciences Holdings, Inc. quarterly revenues are $239.5M, which are larger than Nurix Therapeutics, Inc. quarterly revenues of $7.9M. Harmony Biosciences Holdings, Inc.'s net income of $50.9M is higher than Nurix Therapeutics, Inc.'s net income of -$86.4M. Notably, Harmony Biosciences Holdings, Inc.'s price-to-earnings ratio is 12.24x while Nurix Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings, Inc. is 2.75x versus 19.07x for Nurix Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings, Inc.2.75x 12.24x $239.5M $50.9M NRIXNurix Therapeutics, Inc.19.07x -- $7.9M -$86.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 24.71% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is up 20.67% over the past day.
Buy
84
RKLB alert for Dec 23
Rocket Lab Corp. [RKLB] is up 9.97% over the past day.
